IGF-II Regulates Lysyl Oxidase Propeptide and Mediates Its Effects in Part Via Basic Helix-loop-helix E40

Overview

Journal Matrix Biol

Publisher Elsevier

Specialties Biochemistry
Molecular Biology

Date 2024 Jun 9

PMID 38852924

Authors

Adegboyega Timothy Adewale

Shailza Sharma

Joe E Mouawad

Xinh-Xinh Nguyen

Amy D Bradshaw

Carol Feghali-Bostwick

Affiliations

Soon will be listed here.

Abstract

Pulmonary fibrosis (PF) is a clinically severe and commonly fatal complication of Systemic Sclerosis (SSc). Our group has previously reported profibrotic roles for Insulin-like Growth Factor II (IGF-II) and Lysyl Oxidase (LOX) in SSc-PF. We sought to identify downstream regulatory mediators of IGF-II. In the present work, we show that SSc lung tissues have higher baseline levels of the total (N-glycosylated/unglycosylated) LOX-Propeptide (LOX-PP) than control lung tissues. LOX-PP-mediated changes were consistent with the extracellular matrix (ECM) deregulation implicated in SSc-PF progression. Furthermore, Tolloid-like 1 (TLL1) and Bone Morphogenetic Protein 1 (BMP1), enzymes that can cleave ProLOX to release LOX-PP, were increased in SSc lung fibrosis and the bleomycin (BLM)-induced murine lung fibrosis model, respectively. In addition, IGF-II regulated the levels of ProLOX, active LOX, LOX-PP, BMP1, and isoforms of TLL1. The Class E Basic Helix-Loop-Helix protein 40 (BHLHE40) transcription factor localized to the nucleus in response to IGF-II. BHLHE40 silencing downregulated TLL1 isoforms and LOX-PP, and restored features of ECM deregulation triggered by IGF-II. Our findings indicate that IGF-II, BHLHE40, and LOX-PP may serve as targets of therapeutic intervention to halt SSc-PF progression.

References

Vandenbroucke R, Libert C . Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nat Rev Drug Discov. 2014; 13(12):904-27. DOI: 10.1038/nrd4390. View

Zhao Y, Min C, Vora S, Trackman P, Sonenshein G, Kirsch K . The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem. 2008; 284(3):1385-93. PMC: 2615524. DOI: 10.1074/jbc.M802612200. View

Pardo A, Selman M . Molecular mechanisms of pulmonary fibrosis. Front Biosci. 2002; 7:d1743-61. DOI: 10.2741/pardo. View

Garrett S, Hsu E, Thomas J, Pilewski J, Feghali-Bostwick C . Insulin-like growth factor (IGF)-II- mediated fibrosis in pathogenic lung conditions. PLoS One. 2019; 14(11):e0225422. PMC: 6876936. DOI: 10.1371/journal.pone.0225422. View

Kagan H, Li W . Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003; 88(4):660-72. DOI: 10.1002/jcb.10413. View

Dean R, Cox J, Bellac C, Doucet A, Starr A, Overall C . Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood. 2008; 112(8):3455-64. DOI: 10.1182/blood-2007-12-129080. View

Zheng Y, Wang X, Wang H, Yan W, Zhang Q, Chang X . Expression of the lysyl oxidase propeptide in hepatocellular carcinoma and its clinical relevance. Oncol Rep. 2014; 31(4):1669-76. DOI: 10.3892/or.2014.3044. View

Li X, Liu X, Meng Q, Wu X, Bing X, Guo N . Circadian clock disruptions link oxidative stress and systemic inflammation to metabolic syndrome in obstructive sleep apnea patients. Front Physiol. 2022; 13:932596. PMC: 9466597. DOI: 10.3389/fphys.2022.932596. View

Morse C, Tabib T, Sembrat J, Buschur K, Trejo Bittar H, Valenzi E . Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J. 2019; 54(2). PMC: 8025672. DOI: 10.1183/13993003.02441-2018. View

10.

Mac Sweeney A, Gil-Parrado S, Vinzenz D, Bernardi A, Hein A, Bodendorf U . Structural basis for the substrate specificity of bone morphogenetic protein 1/tolloid-like metalloproteases. J Mol Biol. 2008; 384(1):228-39. DOI: 10.1016/j.jmb.2008.09.029. View

11.

Pilewski J, Liu L, Henry A, Knauer A, Feghali-Bostwick C . Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol. 2005; 166(2):399-407. PMC: 1602317. DOI: 10.1016/S0002-9440(10)62263-8. View

12.

McDonough J, Ahangari F, Li Q, Jain S, Verleden S, Herazo-Maya J . Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight. 2019; 4(22). PMC: 6948862. DOI: 10.1172/jci.insight.131597. View

13.

Cieplak P, Strongin A . Matrix metalloproteinases - From the cleavage data to the prediction tools and beyond. Biochim Biophys Acta Mol Cell Res. 2017; 1864(11 Pt A):1952-1963. PMC: 5831720. DOI: 10.1016/j.bbamcr.2017.03.010. View

14.

Reid R, Mogford J, Butt R, deGiorgio-Miller A, Mustoe T . Inhibition of procollagen C-proteinase reduces scar hypertrophy in a rabbit model of cutaneous scarring. Wound Repair Regen. 2006; 14(2):138-41. DOI: 10.1111/j.1743-6109.2006.00103.x. View

15.

Trackman P, Peymanfar Y, Roy S . Functions and Mechanisms of Pro-Lysyl Oxidase Processing in Cancers and Eye Pathologies with a Focus on Diabetic Retinopathy. Int J Mol Sci. 2022; 23(9). PMC: 9105217. DOI: 10.3390/ijms23095088. View

16.

Hsu E, Feghali-Bostwick C . Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways. Am J Pathol. 2008; 172(6):1580-90. PMC: 2408418. DOI: 10.2353/ajpath.2008.071021. View

17.

Palamakumbura A, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein G . The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem. 2004; 279(39):40593-600. DOI: 10.1074/jbc.M406639200. View

18.

McQuibban G, Gong J, Wong J, Wallace J, Clark-Lewis I, Overall C . Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 2002; 100(4):1160-7. View

19.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

20.

Kiso A, Toba Y, Tsutsumi S, Deguchi S, Igai K, Koshino S . Tolloid-Like 1 Negatively Regulates Hepatic Differentiation of Human Induced Pluripotent Stem Cells Through Transforming Growth Factor Beta Signaling. Hepatol Commun. 2020; 4(2):255-267. PMC: 6996343. DOI: 10.1002/hep4.1466. View